(<i>S</i>)-Spiro[(1,3-diazacyclopent-1-ene)-5,2‘-(7‘-methyl-1‘,2‘,3‘,4‘- tetrahydronaphthalene)]:  Resolution, Stereospecific Synthesis, and Preliminary Pharmacological Characterization as a Partial α-Adrenergic Agonist

Alex Cordi, Jean‐Michel Lacoste, Fabrice Le Borgne, Yolande Hervé, Lucile Vaysse‐Ludot, Jean‐Jacques Descombes, Christine Courchay, Michel Laubie, Tony J. Verbeuren

Journal of Medicinal Chemistry · 1997 · 14 citations · 5 references

Concepts

Abstract

Recently, we reported on the design, synthesis, and structure-activity relationships of a series of spiroimidazolines endowed with alpha-adrenergic agonist activities. Among the compounds described, (R,S)-spiro(1,3-diazacyclopent-1-ene)-[5,2'](7'-methyl-1'2',3', 4',-tetrahydronaphthalene) fumarate (5RS) was chosen for further development as a venotonic agent. The resolution of this compound, as well as the pharmacological characterization of the enantiomers, stereospecific synthesis of eutomer (5S, S 18149), and determination of absolute configuration by single-crystal X-ray diffraction analysis, are described.

References

5